Overactive Bladder
Overactive bladder (OAB) is a symptom complex defined by the International Continence Society as urinary urgency, usually accompanied by increased daytime frequency and nocturia, with or without urinary urge incontinence, in the absence of urinary tract infection or other obvious pathology. The pathogenesis of OAB is multifactorial and involves abnormal detrusor muscle activity, heightened afferent nerve signaling, and altered central nervous system control of bladder function. Neurogenic and myogenic mechanisms, as well as urothelial dysfunction, contribute to this dysregulation, resulting in involuntary detrusor contractions during the bladder filling phase. The health impacts of OAB are significant, affecting physical, psychological, and social well-being. Patients often experience embarrassment, anxiety, and depression, with a marked reduction in quality of life due to the unpredictable nature of symptoms, disruption of daily activities, and sleep disturbances. OAB is associated with increased healthcare utilization, risk of falls and fractures in the elderly, and substantial economic burden.
This type is characterized by the presence of urinary urgency accompanied by involuntary leakage of urine, termed urge urinary incontinence. Patients with this form of OAB experience both the compelling need to void and episodes of incontinence, which may be frequent and severe, significantly impacting daily activities and quality of life.
This subtype involves urinary urgency, frequency, and nocturia without associated urge incontinence. Individuals with this type experience the urgent need to void and increased micturition frequency but are able to reach the toilet in time to avoid leakage. Though incontinence is absent, the symptoms still cause considerable distress and lifestyle limitations.
Neurogenic OAB refers to overactive bladder symptoms resulting from underlying neurological conditions such as multiple sclerosis, Parkinson's disease, spinal cord injury, or stroke. The pathophysiology involves disruption of neural pathways regulating bladder storage and voiding, leading to detrusor overactivity and the classic OAB symptom complex.
Idiopathic OAB denotes cases where no identifiable neurological or anatomical cause can be found. The etiology is presumed to involve complex interactions between bladder smooth muscle, urothelium, and neural control, resulting in the characteristic symptoms without an overt underlying disorder.
Overactive bladder is a prevalent condition worldwide, affecting both men and women across all age groups, though prevalence increases with advancing age. Epidemiological studies estimate the global prevalence of OAB symptoms to be approximately 11–16% in adults, with higher rates observed in individuals over 65 years of age. Women are slightly more likely to report OAB symptoms than men, particularly urge urinary incontinence, while men may experience increased frequency and urgency, often in association with lower urinary tract symptoms due to prostatic enlargement. OAB is underdiagnosed and undertreated, in part due to social stigma and misconceptions regarding normal aging. The condition is associated with significant comorbidities, including depression, anxiety, sleep disorders, and increased risk of falls and fractures in the elderly. The economic impact is substantial, encompassing direct medical costs, productivity loss, and reduced quality of life.
The diagnosis of overactive bladder is primarily clinical, based on the presence of urinary urgency, with or without urge incontinence, usually accompanied by frequency and nocturia, in the absence of infection or other obvious pathology. A thorough medical history and physical examination are essential to rule out alternative causes such as urinary tract infection, bladder stones, malignancy, or anatomical abnormalities. Symptom assessment tools, such as the Overactive Bladder Questionnaire (OAB-q) and bladder diaries, are frequently employed to quantify symptom severity and impact on quality of life. Urinalysis is performed to exclude infection or hematuria, and post-void residual measurement may be indicated to assess for incomplete bladder emptying. Urodynamic studies are reserved for complex cases or when initial management fails, providing objective evidence of detrusor overactivity. Imaging studies, such as ultrasound or cystoscopy, may be warranted if hematuria, recurrent infections, or suspicion of structural abnormalities are present. Diagnostic criteria emphasize the exclusion of other etiologies and the confirmation of the symptom complex characteristic of OAB.
Several pharmacological agents are available for the management of overactive bladder, each targeting different aspects of bladder function. Vibegron is a beta-3 adrenergic receptor agonist that enhances bladder storage by relaxing the detrusor muscle during the filling phase. Solifenacin tartrate and solifenacin succinate are antimuscarinic agents that inhibit muscarinic receptors in the bladder, thereby reducing involuntary detrusor contractions and alleviating urgency and frequency. ATD-oxybutynin, also known as oxybutynin-ATD, is another antimuscarinic medication that acts to decrease bladder muscle overactivity. Mirabegron is a beta-3 adrenergic agonist that increases bladder capacity and reduces symptoms of urgency and frequency. Fesoterodine fumarate is an antimuscarinic drug that provides symptom relief by blocking muscarinic receptors involved in bladder contraction. Combination therapy with tamsulosin hydrochloride and tolterodine tartrate offers both alpha-adrenergic blockade and antimuscarinic effects, targeting both bladder outlet and detrusor muscle overactivity. Imidafenacin is an antimuscarinic agent that selectively inhibits muscarinic receptors in the bladder, reducing involuntary contractions. Darifenacin hydrobromide is a highly selective M3 muscarinic receptor antagonist that suppresses detrusor muscle contractions and improves bladder storage symptoms. Tolterodine tartrate is an antimuscarinic medication that acts to reduce urinary urgency, frequency, and urge incontinence by inhibiting involuntary bladder contractions. These medications are administered according to clinical guidelines and tailored to individual patient profiles, with the aim of optimizing symptom control and improving quality of life.
| Structure | Generic Name | CAS Registry Number | Molecular Formula | Molecular Weight |
|---|---|---|---|---|
 | vibegron (Rec INN; USAN) | 1190389-15-1 | C26 H28 N4 O3 | 444.526 |
 | solifenacin tartrate | 1035547-81-9 | C23 H26 N2 O2 . C4 H6 O6 | 512.552 |
| ATD-oxybutynin; oxybutynin-ATD | ||||
 | mirabegron (Prop INN; USAN) | 223673-61-8 | C21 H24 N4 O2 S | 396.506 |
 | fesoterodine fumarate (Rec INNM; USAN) | 286930-02-7 (free base); 286930-03-8 | C26 H37 N O3 . C4 H4 O4 | 527.649 |
| tamsulosin hydrochloride/tolterodine tartrate | ||||
 | imidafenacin (Rec INN) | 170105-16-5 | C20 H21 N3 O | 319.4 |
 | solifenacin succinate (Rec INNM; USAN) | 242478-38-2 | C23 H26 N2 O2 . C4 H6 O4 | 480.553 |
 | darifenacin hydrobromide (Rec INNM; USAN; BANM) | 133099-07-7 | C28 H30 N2 O2 . Br H | 507.462 |
 | tolterodine tartrate (Rec INNM; USAN) | 124937-51-5 (free base); 124937-52-6 | C22 H31 N O . C4 H6 O6 | 475.574 |
Make Order
Experimental Scheme
Implementation
Conclusion
